z-logo
open-access-imgOpen Access
Cost of AF Ablation: Where Do We Stand?
Author(s) -
Yaariv Khaykin,
Yana Shamiss
Publication year - 2011
Publication title -
cardiology research and practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 35
eISSN - 2090-8016
pISSN - 2090-0597
DOI - 10.4061/2011/589781
Subject(s) - medicine , atrial fibrillation , catheter ablation , ablation , quality of life (healthcare) , intensive care medicine , indirect costs , cardiology , business , nursing , accounting
Atrial fibrillation (AF) is a common and frequently disabling chronic condition associated with significant patient morbidity and affecting an increasing stratum of our ageing society. Direct costs related to atrial fibrillation are comprised from direct cost of medical therapy, catheter ablation, and related hospitalizations and imaging procedures, with indirect costs related to complications of the primary therapeutic strategy, management of related conditions, as well as disability and loss in quality of life related to AF. Over the last decade, catheter ablation became a promising alternative to rate and rhythm control among symptomatic AF patients. The purpose of this paper is to describe the evidence on the financial implications related to ablation based on published data and authors' experience.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom